[Biological function of bone cells on the PTH-driven anabolic effect]
- PMID: 22370304
[Biological function of bone cells on the PTH-driven anabolic effect]
Abstract
Parathyroid hormone (PTH) -driven anabolism in bone appears to involve the osteoblastic activation and the increased population of preosteoblastic lineages. Given that the activities of osteoclasts and osteoblasts are intertwined during normal bone remodeling, it is plausible that the anabolic action of PTH is either directly or indirectly related to the osteoclast. We have recently reported that the absence of osteoclasts in c-fos( - / - ) mice might hinder PTH-driven bone anabolism, and that osteoclastic presence may be necessary for full osteoblastic differentiation and enhanced bone formation seen after intermittent PTH administration. Alternatively, it was suggested that PTH administration inhibits sclerostin synthesis by osteocytes, thereby allowing for active bone formation. Taken together, PTH affects bone cells in a dual pathway - mediating osteoblastic (preosteoblastic) activities or osteocytic synthesis of sclerostin -.
Similar articles
-
[Bone histology after intermittent PTH treatment - animal models -].Clin Calcium. 2013 Mar;23(3):347-53. Clin Calcium. 2013. PMID: 23445886 Review. Japanese.
-
Does osteocytic SOST suppression mediate PTH bone anabolism?Trends Endocrinol Metab. 2010 Apr;21(4):237-44. doi: 10.1016/j.tem.2009.12.002. Epub 2010 Jan 13. Trends Endocrinol Metab. 2010. PMID: 20074973 Review.
-
Parathyroid hormone temporal effects on bone formation and resorption.Bull Math Biol. 2000 Jan;62(1):163-88. doi: 10.1006/bulm.1999.0146. Bull Math Biol. 2000. PMID: 10824426
-
Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans.Scand J Clin Lab Invest. 2012 Feb;72(1):14-22. doi: 10.3109/00365513.2011.624631. Epub 2011 Nov 16. Scand J Clin Lab Invest. 2012. PMID: 22085136 Review.
-
The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics.J Endocrinol Invest. 2011 Jul;34(7 Suppl):18-22. J Endocrinol Invest. 2011. PMID: 21985975 Review.